Reexpression of hypermethylated tumor suppressor genes using DNA methyltransferase (DNMT) and histone deacetylase inhibitors occurs by a mechanism whereby promoter demethylation is the dominant event. In support of this model, we found in acute myeloid leukemia cells with hypermethylated p15INK4B and E-cadherin promoters that the DNMT inhibitor, 5-aza-2 0 -deoxycytidine, induced p15INK4B and E-cadherin expression, and decreased levels of DNA methylation, histone H3 lysine 9 (H3K9) methylation and SUV39H1 associated with p15INK4B and Ecadherin promoters. On the basis of these observations, we examined whether promoter demethylation was dominant to H3K9 demethylation in p15INK4B and E-cadherin reexpression. We observed that SUV39H1 short hairpin RNA and chaetocin, a SUV39H1 inhibitor, induced p15INK4B and E-cadherin expression and H3K9 demethylation without promoter demethylation. Reexpression of hypermethylated p15INK4B and E-cadherin required histone H3K9 demethylation that was achieved directly by inhibiting SUV39H1 expression or activity, or indirectly by decreasing the amount of SUV39H1 associated with the p15INK4B and E-cadherin promoters using 5-aza-2 0 -deoxycytidine. The results from this study highlight the potential of H3K9 methyltransferases as therapeutic targets for reactivating expression of hypermethylated genes.
Introduction
Epigenetic changes contribute to transcriptional deregulation in myeloid neoplasia, and aberrant promoter methylation is a critical mechanism of tumor suppressor gene inactivation in these and other cancers (Issa, 2003; Baylin, 2005) . DNA methylation is widespread in acute myeloid leukemia (AML) (Galm et al., 2006) , and many genes, including p15INK4B (p15) and E-cadherin, are inactivated by promoter hypermethylation (Melki et al., 2000; Boultwood and Wainscoat, 2007) . The potentially reversible epigenetic changes in neoplasia present new opportunities for the clinical management of cancer. In support of this notion, the DNA methylation inhibitor, 5-aza-2 0 -deoxycytidine (5-Aza-dC), has shown good therapeutic efficacy in AML clinical trials.
Although epigenetic changes are reversible in experimental systems, aberrant promoter methylation and gene silencing return once 5-Aza-dC treatment is stopped (Pfeifer et al., 1990) . Persistent gene activation may require targeting of multiple components of the epigenetic silencing mechanism. Synergistic affects of 5-Aza-dC and histone deacetylase (HDAC) inhibitors on reexpression of genes transcriptionally silenced by epigenetic modifications have been observed in in vitro systems (Cameron et al., 1999) . Therapeutic strategies that incorporate epigenetic drug combinations in AML treatment are being developed (Gilbert et al., 2004) , with promising results seen in a small series of patients (Gore et al., 2006) . Despite the ability of HDAC inhibitors to work synergistically with 5-Aza-dC in enhancing reexpression of genes silenced by promoter hypermethylation, they do not block resilencing of gene expression after 5-Aza-dC treatment (Egger et al., 2007) . Devising cancer therapy that is based on the persistent reversal of abnormal promoter methylation requires a more detailed understanding of how promoter methylation silences genes in cancer .
Promoter methylation by itself may not initiate gene silencing or directly repress transcription . The existence of epigenetic interactions between DNA methylation and histone modifications leading to transcriptional silencing is well established; however, the precise sequence of events is not known (Fuks, 2005) . Evidence supports the influence of DNA methylation on histone modifications. For example, DNA methyltransferases (DNMTs) and methyl-CpGbinding proteins recruit repressor complexes containing HDAC activity (Bird, 2002) . Other studies have shown that histone modifications are a prerequisite for DNA methylation. In mammals, DNMTs interact with SUV39H1 histone H3 lysine 9 (H3K9) methyltransferase (Fuks et al., 2003a; Lehnertz et al., 2003) . Loss of H3K9 methylation in SUV39H1 knockout embryonic stem cells decreases DNMT3b-dependent CpG methylation at major centromere satellites (Lehnertz et al., 2003) . In addition, H3K9 methylation and p16 silencing can occur before CpG methylation (Bachman et al., 2003) . Recently, it has been shown that expression of p15 antisense RNA causes silencing of p15 sense mRNA by increasing H3K9 dimethylation and decreasing H3K4 dimethylation without changing DNA methylation (Yu et al., 2008) . p15 antisense RNA expression only affected DNA methylation when they were expressed in embryonic stem cells that were differentiated to form embryoid bodies (Yu et al., 2008) . These observations suggest that DNA methylation may be a secondary event in gene silencing and that only genes silenced by other mechanisms are subject to CpG methylation (Bird, 2002; Mutskov and Felsenfeld, 2004) .
Together, methylated DNA and histone modifications form the basis for an epigenetic program that leads to transcriptional silencing. Epigenetic information can flow from histones to DNA and back again. For example, methylation of H3K9 creates a binding site for an adaptor molecule, such as HP1, which in turn recruits DNMT activity. DNMTs catalyse DNA methylation, which in turn recruit methyl-CpG-binding proteins. Bound methyl-CpG-binding proteins then recruit HDACs, which prime H3K9 sites for methylation. Other variations to this flow of information would include the DNMT-HDAC interaction, initiating the priming of H3K9 sites for methylation (Fuks, 2005) .
Currently, it is not clear whether the same mechanisms will apply to reexpressing genes silenced by promoter methylation. In the collaboration between DNA methylation and histone deacetylation that silences gene expression, DNA methylation seems to be dominant. Hence, drugs that inhibit histone deacetylation can increase expression of genes without methylated promoters, but they cannot induce expression of hypermethylated genes in cancer cells (Suzuki et al., 2002; Mutskov and Felsenfeld, 2004) . However, if some demethylation is caused by low doses of drugs, then HDAC inhibitors are synergistic with demethylation for reexpressing epigenetically silenced genes (Cameron et al., 1999; Suzuki et al., 2002) . Similar studies have not been performed to determine the effect of blocking H3K9 methylation on gene reexpression and to establish whether this event is dominant to DNA methylation.
Here, we analysed effects of DNA and histone H3K9 methylation inhibitors on reexpression of p15 and E-cadherin. Hypermethylation of p15, an inhibitor of CDK4 and a negative regulator of cell cycle, occurs in the majority of patients with AML (Herman et al., 1997) . Hypermethylation of E-cadherin is observed in AML (Melki et al., 1999 (Melki et al., , 2000 Shimamoto et al., 2005) , although the biological significance is unclear. We found that 5-Aza-dC induced expression of p15 and E-cadherin in AML cells with hypermethylated p15 and E-cadherin promoters. To determine whether promoter demethylation was dominant to H3K9 demethylation, we monitored p15 and E-cadherin reexpression in the presence of SUV39H1 short hairpin RNA (shRNA) or the SUV39H1 inhibitor, chaetocin. SUV39H1 shRNA and chaetocin induced p15 and E-cadherin expression and H3K9 demethylation; however, they did not alter p15 and E-cadherin promoter methylation. Our results show that hypermethylated p15 and E-cadherin can be reactivated in AML cells by an initial event that involves H3K9 demethylation and does not require promoter demethylation.
Results
p15 and E-cadherin expression and promoter methylation in AML cell lines We examined p15 and E-cadherin expression and promoter methylation in AML cell lines HL60, KG1, KG1a, AML-193 and Kasumi. For p15, promoter methylation patterns in KG1 and KG1a cell lines have been shown to model those observed in AML patients (Herman et al., 1996b; Dodge et al., 2001) . Using reverse transcriptase PCR, we detected p15 and E-cadherin expression only in positive control cell lines HL60 and HeLa, respectively ( Figure 1a) . We determined the methylation status of p15 and E-cadherin promoters in AML cell lines using methylation-specific PCR ( Figure 1b ) and temporal temperature gradient gel electrophoresis (Guldberg et al., 2002; Scott et al., 2006) (Supplementary Figure 1) , and quantified methylation using DNA pyrosequencing (Tost and Gut, 2007) (Supplementary Figure 2 and Supplementary Table 2 ). The p15 promoter was heavily methylated in AML-193, KG1a and Kasumi, partially methylated in KG1 and unmethylated in HL60 (Figure 1b) . The E-cadherin promoter was heavily methylated in AML-193, KG1a and Kasumi, and partially methylated in KG1 (Figure 1b) . 5-Aza-dC demethylates p15 and E-cadherin promoters and induces expression 5-Aza-2 0 -deoxycytidine has been effectively used to reexpress genes silenced by promoter hypermethylation (Egger et al., 2004) . We optimized 5-Aza-dC-induced DNA demethylation using the p15 promoter in AML-193. Unmethylated p15 alleles were detected by 60 h of 5-Aza-dC exposure at all doses (0.5-8 mM), with p15 transcripts reproducibly detected at doses X4 mM (Supplementary Figure 1) . We then used DNA pyrosequencing to examine the effect of 5-Aza-dC on p15 and E-cadherin promoter demethylation in AML-193, KG1a and Kasumi, which have densely methylated promoters. 5-Aza-dC treatment decreased promoter methylation (Figure 1c . 5-Aza-dC treatment results in decreased H3K9 methylation in regulatory regions of silenced genes (Fahrner et al., 2002; Nguyen et al., 2002; Coombes et al., 2003; Kondo et al., 2003) . More recently, 5-Aza-dC has been shown to reduce H3K9 dimethylation in the promoter regions of DSC3 and MASPIN (Wozniak et al., 2007) , and H3K9 trimethylation in the promoter regions of TMS1/ASC (Zhang et al., 2007) . We used chromatin immunoprecipitation (ChIP) assays with anti-dimethyl-H3K9 and antitrimethyl-H3K9 antibodies to analyse the effect of 5-Aza-dC on p15 and E-cadherin promoter H3K9 di-and trimethylation. 5-Aza-dC decreased both H3K9 di-and trimethylation levels relative to the untreated control (Figures 2a and b) . Levels of trimethyl-H3K9 decreased to a greater extent than did dimethyl-H3K9 in response to 5-Aza-dC treatment. We did not observe any changes in histone H3 levels, E-cadherin
Relative Expression Figure 1 p15 and E-cadherin expression and promoter methylation in myeloid leukemia cell lines. (a) Analysis of p15 and E-cadherin expression in acute myeloid leukemia (AML) cell lines using reverse transcriptase PCR. PCR-negative control (dH 2 O) and reverse transcriptase-negative control (RTÀ) are indicated. b-Actin expression levels were used as cDNA input controls. (b) Methylationspecific PCR analysis of p15 and E-cadherin promoter methylation. U and M indicate amplicons generated using primers specific for unmethylated and methylated p15 and E-cadherin promoter alleles, respectively. METH þ denotes methylation-positive control and dH 2 O is a negative control with no PCR template. (c) DNA pyrosequencing analysis of p15 and E-cadherin promoter demethylation in the absence (À) or presence ( þ ) of 5-aza-2 0 -deoxycytidine (5-Aza-dC) (AML-193: p15 (1 mM), E-cadherin (8 mM); Kasumi: p15 and E-cadherin (4 mM); KG1a: p15 and E-cadherin (4 mM)). Percentage methylation is the mean methylation of CpGs in p15 and E-cadherin promoters. (d) Real-time PCR analysis of p15 and E-cadherin mRNA expression. p15 and E-cadherin expression were normalized to HPRT (hypoxanthine-guanine phosphoribosyltransferase) expression. p15 and E-cadherin expression in 5-Aza-dC-treated cells were reported relative to untreated cells. Error bars represent standard deviation from three independent measurements. (c and d) '**' Represents P-value o0.01 and '*' represents P-value o0.05 between 5-Aza-dC-treated and untreated cells.
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A Lakshmikuttyamma et al indicating that changes in histone H3K9 methylation were not due to nucleosome depletion ( Figure 2c ). Western analysis of H3K9 methylation in response to 5-Aza-dC showed that reduced H3K9 methylation at p15 and E-cadherin promoters detected by ChIP were local changes and did not reflect global changes in H3K9 methylation ( Figure 2d ). As trimethyl-H3K9 decreased the most in response to 5-Aza-dC, we used ChIP assays with an anti-SUV39H1 antibody to determine whether SUV39H1 association with p15 and E-cadherin promoters changed in response to 5-Aza-dC. SUV39H1 catalyses H3K9 trimethylation (Rea et al., 2000) at pericentric heterochromatin (Peters et al., 2001) and at euchromatic promoters (Nielsen et al., 2001 (Nielsen et al., , 2006 Vandel et al., 2001; Chakraborty et al., 2003; Macaluso et al., 2003; Narita et al., 2003; Nicolas et al., 2003; Carbone et al., 2006; Kamoi et al., 2006; Mal, 2006; Jang et al., 2007; Cattaneo and Nucifora, 2008; Spensberger and Delwel, 2008) . 5-Aza-dC reduced the association of SUV39H1 with p15 and E-cadherin promoters in AML cell lines (Figure 2e ). These results suggest that reduction in trimethyl-H3K9 at p15 and E-cadherin promoters in response to 5-Aza-dC was due to decreased association of SUV39H1. ChIP PCR products were amplified from input-positive controls, IgG-negative controls and antibody immunoprecipitates. Histograms show antibody/input ratios of PCR products quantified using real-time PCR. Error bars represent standard deviation from three independent measurements. '**' Represents P-value o0.01 and '*' represents P-value o0.05 between 5-Aza-dC-treated and untreated cells.
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Inhibition of SUV39H1 activity and expression induces p15 and E-cadherin expression As 5-Aza-dC dissociated SUV39H1 from p15 and E-cadherin promoters, we investigated whether reduction in SUV39H1 activity or expression would increase p15 and E-cadherin expression. First, we monitored p15 and E-cadherin expression in the presence of SUV39H1 shRNA. Transfection of AML-193 and KG1 with SUV39H1 shRNA reduced SUV39H1 expression, as determined by western analysis (Figure 3a ). KG1a and Kasumi have low transfection efficiency and were not used for shRNA experiments. SUV39H1 shRNA treatment enhanced p15 and E-cadherin expression at levels similar to 5-Aza-dC (Figure 3b ). To further confirm the importance of SUV39H1 in repressing p15 and E-cadherin, we monitored p15 and E-cadherin expression in the presence of various concentrations of the SUV39H1 inhibitor, chaetocin (Greiner et al., 2005) . We observed that 100-200 nM of chaetocin induced p15 and E-cadherin expression in AML-193 and KG1 cells (Figure 3c ). Similar results were observed for KG1a and Kasumi cells (Supplementary Figure 3) .
Inhibition of SUV39H1 activity and expression reduces H3K9 methylation in p15 and E-cadherin promoters To determine whether chaetocin inhibited H3K9 methylation at p15 and E-cadherin promoters, we used ChIP assays with anti-dimethyl-H3K9 and anti-trimethyl-H3K9 antibodies. Similar to the results observed with 5-Aza-dC, chaetocin decreased levels of trimethyl-H3K9 to a greater extent than did dimethyl-H3K9 for both p15 and E-cadherin promoters (Figures 4a and b) . We did not observe any changes in histone H3 levels, indicating that changes in histone H3K9 methylation were not due to nucleosome depletion (Figure 4c ). These effects appear to be local changes at p15 and E-cadherin promoters, as chaetocin did not alter the global levels of H3K9 di-and trimethylation (Figure 2d ). To further confirm the importance of SUV39H1 in regulating H3K9 methylation, we used ChIP assay to assess levels of histone H3K9 di-and trimethylation at p15 and E-cadherin promoters after treatment with SUV39H1 shRNA in AML-193 cells (Figure 4d ). Similar to chaetocin, SUV39H1 shRNA decreased levels of trimethyl-H3K9 to a greater extent than did dimethyl-H3K9 for both p15 and E-cadherin promoters. These effects seem to be local changes at the p15 and E-cadherin promoters, as SUV39H1 shRNA did not alter the global levels of H3K9 di-and trimethylation (Figure 4e ).
Inhibition of SUV39H1 enhances p15 and E-cadherin expression without promoter demethylation The ability of chaetocin and SUV39H1 shRNA to enhance p15 and E-cadherin expression in the absence of Table 2) . To confirm that p15 and E-cadherin promoters were not demethylated by chaetocin in regions besides the area analysed by pyrosequencing, we performed bisulfite sequencing on the CpG islands in the p15 and E-cadherin promoters. Previously, it has been shown that hTERT (human telomerase reverse transcriptase) is expressed in the presence of promoter methylation by maintaining unmethylated DNA and active chromatin around the transcription start site (Zinn et al., 2007) . For p15 and E-cadherin, we did not observe any changes in CpG island methylation in response to chaetocin treatment (Supplementary Figure 4) .
Inhibition of SUV39H1 decreases proliferation and viability, and enhances apoptosis
We analysed the effect of chaetocin and SUV39H1 shRNA on cell proliferation, viability and apoptosis in AML-193 cells. Chaetocin and SUV39H1 shRNA caused a substantial decrease in cell proliferation and viability, and an increase in apoptosis (Figures 6a-c) . Similar effects for chaetocin and SUV39H1 shRNA were also observed in KG1 (Supplementary Figure 5) .
Discussion
Increased p15 and E-cadherin methylation density is associated with advanced myelodysplastic syndrome and AML (Melki et al., 1999 (Melki et al., , 2000 Christiansen et al., 2003; Baylin, 2005) , and there is interest in using epigenetic inhibitors to treat these diseases at doses that reverse methylation, but have low cytotoxicity (Gore, 2005) . We identified AML-193, Kasumi and KG1a as model cell lines for examining strategies to reexpress genes silenced by promoter hypermethylation. Treatment of these cells lines with 5-Aza-dC enhanced p15 and E-cadherin expression, and decreased promoter and histone H3K9 methylation. Decreased H3K9 methylation represented a local change in chromatin structure, as 5-Aza-dC-induced demethylation of p15 and Ecadherin promoters did not alter global levels of H3K9 methylation. The ability of 5-Aza-dC to augment expression and chromatin remodeling of a small number of unmethylated genes in vitro (Nguyen et al., 2002; Coombes et al., 2003; Wu et al., 2005; Scott et al., 2006) suggests that it may have effects that are independent of cytosine demethylation. As the p15 and E-cadherin promoters in AML-193, Kasumi and KG1a cells were methylated at both alleles, demethylation-independent effects of 5-Aza-dC that may occur with hemimethylated alleles or mixed populations of hypermethylated and unmethylated alleles were limited. Histone H3K9 methylation is associated with silent heterochromatic regions; however, the exact role that this modification has in epigenetic processes is not fully understood. Among the methyltransferases that can methylate H3K9, SUV39H1 is the main methyltransferase for the trimethylation of H3K9, and G9a is the main methyltransferase for mono and dimethylation of H3K9 (Kurokawa et al., 1998; Tachibana et al., 2002; Rice et al., 2003; Mal, 2006) . The degree of H3K9 methylation is associated with distinct chromatin regions and transcriptional states. Trimethyl-H3K9 is most commonly associated with pericentromeric heterochromatin and transcriptional repression, whereas dimethyl-H3K9 is associated with genes that are repressed in euchromatic SUV39H1 inhibition reactivates p15INK4B and E-cadherin expression A Lakshmikuttyamma et al regions (Kurokawa et al., 1998; Christiansen et al., 2003; Rice et al., 2003; Mal, 2006) . SUV39H1-mediated repression, however, is not limited to pericentromeric heterochromatin regions, as SUV39H1 activity is also associated with the silencing of several euchromatic genes (Nielsen et al., 2001 (Nielsen et al., , 2006 Vandel et al., 2001; Chakraborty et al., 2003; Macaluso et al., 2003; Narita et al., 2003; Nicolas et al., 2003; Carbone et al., 2006; Kamoi et al., 2006; Mal, 2006; Jang et al., 2007; Cattaneo and Nucifora, 2008; Spensberger and Delwel, 2008 ).
SUV39H1 interacts with several DNA-binding proteins involved in leukemogenesis, such as AML1 (Runx1) (Chakraborty et al., 2003) , PML-RARa (Carbone et al., 2006) and Evi1 (Cattaneo and Nucifora, 2008; Spensberger and Delwel, 2008) , whereby SUV39H1 promotes the silencing of their target genes. Establishment of aberrant p15 and E-cadherin silencing may result from increased association of SUV39H1 with their promoters through interactions with DNA-binding proteins. We showed that SUV39H1 was associated with p15 and E-cadherin promoters; however, the Error bars in (a) and (b) represent standard deviation from three independent experiments, and '*' represents P-value o0.05 and '**' represents P-value o0.01 between treated and untreated cells.
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A Lakshmikuttyamma et al mechanism for this association has not been established. Evi1 is a possible candidate for targeting SUV39H1 to the p15 promoter, as Evi1 interacts with Smad3 and represses TGF-b-induced activation of the p15 promoter (Liu et al., 2005) . E-cadherin promoter contains AML1-binding sites (Bannister et al., 2001) , and thus it is possible that AML1 may recruit SUV39H1 to repress E-cadherin expression. Establishment of SUV39H1-mediated H3K9 methylation may be the initiation event leading to aberrant promoter methylation. Studies have shown that histone modifications are a prerequisite for DNA methylation. In mammals, DNMTs interact with SUV39H1 (Lehnertz et al., 2003; Fuks et al., 2003a) and loss of H3K9 methylation in a SUV39H1 knockout embryonic stem cell decreases DNMT3b-dependent CpG methylation at major centromere satellites (Lehnertz et al., 2003) . In addition, H3K9 methylation and p16 silencing can occur before CpG methylation (Bachman et al., 2003) . These observations suggest that DNA methylation may be a secondary event in gene silencing and that only genes silenced by other mechanisms are subject to CpG methylation (Bird, 2002; Mutskov and Felsenfeld, 2004) . The heterochromatic adaptor protein HP1 may function as a bridging protein that activates DNA methylation in response to H3K9 methylation. HP1 binds methylated histone H3K9 (Lachner et al., 2001; Li et al., 2002) and mediates gene silencing and represses transcription (Nielsen et al., 2001) . HP1 interacts with SUV39H1 (Pruitt et al., 2006) and DNMTs (Lehnertz et al., 2003; Fuks et al., 2003a; Fuks, 2005) . Therefore, epigenetic gene silencing may be established by SUV39H1-mediated H3K9 methylation, which leads to HP1 and DNMT binding and formation of a repressive complex consisting of methylated H3K9 and DNA.
The ability of 5-Aza-dC to inhibit DNMTs and reduce histone H3K9 methylation suggests that DNA methylation helps maintain histone methylation. DNMTs associate with a complex that includes HDAC activity and SUV39H1 (Nguyen et al., 2002) , and DNA methylation recruits methyl-CpG-binding proteins. Bound methyl-CpG-binding proteins then recruit HDACs, which prime H3K9 sites for methylation. Dissociation of this complex would allow histone acetyltransferases to cause a local enrichment of acetylated histones. This model is supported by studies on the hypermethylated p16 gene (Nguyen et al., 2002; Coombes et al., 2003; Kondo et al., 2003) and MLH1 gene (Fahrner et al., 2002) in solid tumor cell lines. Our study builds on this model by showing that in addition to reducing promoter and H3K9 methylation, 5-Aza-dC reduced the association of SUV39H1 with p15 and E-cadherin promoters. Further, we showed that H3K9 demethylation was dominant over promoter demethylation in reexpressing genes silenced by promoter hypermethylation. We observed that genes silenced by promoter hypermethylation were reexpressed by reducing the expression or blocking the activity of SUV39H1 without promoter demethylation. Similar observations have been observed when the activity of the class III HDAC SIRT1 (silent mating type information regulation 2 homolog 1) is inhibited (McGarvey et al., 2007) . SIRT1 inhibition enhances H3K9 acetylation and gene reexpression without promoter demethylation (McGarvey et al., 2007) . Loss of EZH2 histone H3K27 methyltransferase activity also has a similar effect on basally expressed genes (Pruitt et al., 2006) . Inhibition of EZH2 increases expression of basally expressed genes without promoter demethylation; however, unlike SUV39H1 and SIRT1, it has no effect on genes silenced by densely hypermethylated promoters (Pruitt et al., 2006) .
There have been some reported controversies regarding the relationship between p15 promoter methylation and expression (Preisler et al., 2001; Teofili et al., 2003; Ogawa et al., 2007 , Jiemjit et al., 2008 . Ogawa et al. (2007) showed that some patients with low levels of expression also have low levels of p15 promoter methylation, which suggests that promoter methylation-independent mechanisms also regulate p15 expression. In this study, some patients with p15 promoter methylation have increased H3K9 methylation; however, H3K9 methylation at the p15 promoter is also observed in the absence of DNA methylation (Ogawa et al., 2007) . These results highlight the importance of H3K9 methylation in silencing p15 expression.
Our results allow us to rationalize two strategies for reexpressing genes silenced by promoter hypermethylation. The first strategy requires DNMT1 and SUV39H1 to be dissociated from the hypermethylated promoter, which can be accomplished by treating cells with 5-AzadC. Dissociation of DNMT1 and SUV39H1 results in decreased promoter and H3K9 methylation, and enhanced gene expression. The second strategy requires inhibition of SUV39H1 activity. This can be accomplished by inhibiting SUV39H1 expression or methyltransferase activity, which results in decreased H3K9 methylation and enhanced gene expression.
Finally, our findings have potential relevance for designing novel epigenetic therapies. Drugs that affect the epigenetic machinery, such as DNMT and HDAC inhibitors, are becoming more common as cancer therapeutics, particularly in leukemias. The addition of SUV39H1 inhibitors into epigenetic drug therapies may further enhance their activities. As reexpression of p15 and E-cadherin in AML cell lines converges on the requirement for inhibiting H3K9 methylation and does not require promoter demethylation, it is possible that SUV39H1 inhibitors may replace DNMT1 inhibitors in epigenetic therapies. Alternatively, SUV39H1 inhibitors may function synergistically with DNMT and HDAC inhibitors to enhance gene reactivation and chromatin changes. Our study highlights the need for developing more inhibitors of histone methyltransferases and the need for detailed drug interaction studies to identify the best drug combinations and order of additions for optimal epigenetic therapies.
Materials and methods
Reagents and antibodies 5-Aza-2 0 -deoxycytidine, chaetocin and b-actin mouse antibody were obtained from Sigma-Aldrich (Oakville, ON, Canada). SUV39H1 inhibition reactivates p15INK4B and E-cadherin expression A Lakshmikuttyamma et al SUV39H1, H3, dimethyl-H3K9 and trimethyl-H3K9 were from Upstate Biotechnology (Charlottesville, VA, USA). SUV39H1 shRNA and control shRNA plasmids were from Open Biosystems (Huntsville, AL, USA).
Cell lines and culture HL60, HeLa, KG1, KG1a, Kasumi and AML-193 cell lines were purchased from DSMZ (Braunschweig, Germany) and maintained in Iscove's modified Dulbecco's medium with 20% fetal calf serum and penicillin/streptomycin. AML-193 cells were supplemented with granulocyte-macrophage colonystimulating factor (2 ng/ml) and IL-3 (3 U/ml) (R&D, Minneapolis, MN, USA).
Drug treatment 5-aza-2
0 -deoxycytidine and chaetocin were used at concentrations indicated in figure legends. For SUV39H1 shRNA transfections and 5-Aza-dC treatment, cells were treated with 5-Aza-dC for 12 h and then transfected with control or SUV39H1 shRNA and cultured in the presence of 5-Aza-dC.
Transient transfection
Transient transfection was performed using Amaxa Nucleofector system (ESBE Scientific Markham, ON, Canada). Cells (5 Â 10 6 ) were suspended in Nucleofector solution V and 5 mg of SUV39H1 shRNA or control shRNA were transfected using Nucleofector program T-001.
Reverse transcriptase PCR Total RNA was harvested using TRIzol (Invitrogen, Burlington, ON, Canada). cDNA (complementary DNA) was synthesized from 2 mg of total RNA using iScript cDNA synthesis kit (BioRad laboratories, Hercules, CA, USA). PCR was performed in 50 ml reaction mixtures containing 1.0 ml of cDNA, 1 Â Qiagen buffer, 0.2 mM of each dNTP, 0.2 mM of each primer and 1.5 U of HotStar Taq (Qiagen, Valencia, CA, USA). Reactions consisted of 1 cycle at 95 1C for 15 min followed by 35 amplification cycles (94 1C for 1 min, 61 1C for 1 min and 72 1C for 1 min) for p15. E-cadherin PCR was performed using the same conditions except for the annealing temperature. Primer sequences and annealing temperatures are listed in Supplementary Table 1 .
Real-time PCR
Complementary DNA was amplified in a 25 ml reaction containing 12.5 ml SybrGreen PCR Master Mix (Bio-Rad), 100 pmol primers and 0.25 mg cDNA using a Mini-Opticon Real-Time PCR machine (Bio-Rad) with the following program for p15: 1 cycle at 95 1C for 5 min; 45 cycles at 95 1C for 45 s, 55 1C 45 s, 72 1C for 45 s. E-cadherin PCR was performed using the same conditions except the annealing temperature. Primer sequences for p15, E-cadherin and hypoxanthineguanine phosphoribosyltransferase are listed in Supplementary  Table 1 . Hypoxanthine-guanine phosphoribosyltransferase expression was used to normalize mRNA expression.
Methylation-specific PCR DNA methylation within the CpG islands of the p15 and Ecadherin promoters were analysed using methylation-specific PCR after sodium bisulfite treatment of genomic DNA as described previously (Herman et al., 1996a) . CpGenome universally methylated DNA (Chemicon, Temecula, CA, USA), after bisulfite modification, served as the methylated p15 and E-cadherin-positive control. PCR was performed in 50 ml reaction mixtures containing 1.0 ml of modified DNA, 1 Â Qiagen buffer, 2.5 mM MgCl 2 , 0.2 mM of each dNTP, 0.2 mM of each primer and 1.5 U of HotStar Taq (Qiagen). p15 reaction consisted of 1 cycle at 95 1C for 15 min followed by 35 amplification cycles (94 1C for 1 min, 60 1C for 1 min and 72 1C for 1.5 min). E-cadherin PCR was performed using the same conditions except the annealing temperature. Primer sequences and annealing temperatures are listed in Supplementary Table 1.
Pyrosequencing
Pyrosequencing was carried out using PCR product generated from bisulfate-treated DNA. PCR was performed in 50 ml reaction mixtures containing 1.0 ml of bisulfate-modified DNA, 1 Â Qiagen PCR buffer, 2.0 mM MgCl 2 , 0.2 mM of each dNTP, 0.2 mM of each primer and 1. 
Chromatin immunoprecipitation
Chromatin immunoprecipitation assays were performed using the ChIP assay kit from Upstate Biotechnology. The following precipitating antibodies were used in the listed quantities: anti-SUV39H1, 10 mg; anti-H3 4.0 mg; anti-H3-dimethyl-K9, 4.0 mg; anti-H3-trimethyl-K9, 4.0 mg. Assays were performed as described by Upstate Biotechnology. Real-time PCR amplification of p15 and E-cadherin promoter regions was performed on diluted input, IgG control and positive antibody DNA samples using primer sequences listed in Supplementary Table 1 .
Western analysis
Total protein lysates and western blotting analysis was performed as previously described (Pastural et al., 2007) .
Cell proliferation assay
Cell proliferation was measured using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays after 72 h of drug treatment or transfection as previously described (Fahrner et al., 2002) .
Cell viability assay
Cell viability was determined using Trypan blue (Invitrogen) dye exclusion assay after 72 h of drug treatment or transfection.
Cell cycle analysis
Cell cycle analysis was performed as previously described after 48 h of drug treatment or transfection (Scott et al., 2007) .
Statistical analysis
All the data are reported as mean and standard deviation. The differences between the mean values were tested for statistical significance by the two-tailed Student's t-test (P-values).
